Edition:
India

Edwards Lifesciences Corp (EW.N)

EW.N on New York Stock Exchange

112.03USD
19 Oct 2017
Change (% chg)

$0.83 (+0.75%)
Prev Close
$111.20
Open
$111.42
Day's High
$112.20
Day's Low
$110.86
Volume
305,615
Avg. Vol
311,207
52-wk High
$121.44
52-wk Low
$81.13

Chart for

About

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan... (more)

Overall

Beta: 0.49
Market Cap(Mil.): $23,656.03
Shares Outstanding(Mil.): 211.16
Dividend: --
Yield (%): --

Financials

Edwards Lifesciences raises 2017 forecast after strong quarter

July 26 Edwards Lifesciences Corp on Wednesday provided a revised full-year earnings forecast with the new low end of the range above Wall Street estimates, and it posted higher-than-expected second-quarter profit on double-digit growth in sales of its transcatheter heart valve replacements.

27 Jul 2017

BRIEF-Edwards' Inspiris Resilia valve receives FDA approval

* Edwards Lifesciences Corp - Received U.S. FDA approval for its Inspiris Resilia aortic valve, first in a new class of resilient heart valves Source text for Eikon: Further company coverage:

05 Jul 2017

BRIEF-Neovasc says German Court partially found in favor of Edwards Lifesciences in its case against co

* District court in Munich has partially found in favour of Edwards Lifesciences Corporation in its case against Neovasc

16 Jun 2017

BRIEF-Edwards Lifesciences says SAPIEN 3 valve receives FDA approval for aortic, mitral valve-in-valve procedures

* Edwards SAPIEN 3 valve receives FDA approval for aortic, mitral valve-in-valve procedures Source text for Eikon: Further company coverage:

06 Jun 2017

FDA approves new use for Edwards' Sapien 3 heart valve

The U.S. Food and Drug Administration on Monday approved Edwards Lifesciences Corp's Sapien 3 artificial heart valve for high-risk patients whose previously implanted heart valves are failing, a procedure designed to avoid repeat open heart surgery.

06 Jun 2017

UPDATE 1-FDA approves new use for Edwards' Sapien 3 heart valve

June 5 The U.S. Food and Drug Administration on Monday approved Edwards Lifesciences Corp's Sapien 3 artificial heart valve for high-risk patients whose previously implanted heart valves are failing, a procedure designed to avoid repeat open heart surgery.

06 Jun 2017

FDA approves new use for Edwards' Sapien 3 heart valve

June 5 The U.S. Food and Drug Administration on Monday approved Edwards Lifesciences Corp's Sapien 3 artificial heart valve for high-risk patients whose previously implanted heart valves are failing, a procedure designed to avoid repeat open heart surgery.

06 Jun 2017

BRIEF-Edwards Lifesciences Q1 earnings per share $1.06

* Says Q1 earnings per share $1.06; Q1 adjusted earnings per share $0.94; Q1 sales grew 27 percent to $884 million

26 Apr 2017

Edwards profit tops expectations on soaring heart valve sales

April 25 Edwards Lifesciences Corp on Tuesday reported higher-than expected first-quarter profit and revenue on surging sales of transcatheter heart valve replacements, and raised its full-year earnings forecast to reflect the strong start to the year.

26 Apr 2017

Earnings vs. Estimates